vs
Side-by-side financial comparison of bioAffinity Technologies, Inc. (BIAF) and CXApp Inc. (CXAI). Click either name above to swap in a different company.
bioAffinity Technologies, Inc. is the larger business by last-quarter revenue ($1.6M vs $1.0M, roughly 1.6× CXApp Inc.). bioAffinity Technologies, Inc. runs the higher net margin — -197.0% vs -544.1%, a 347.2% gap on every dollar of revenue. On growth, bioAffinity Technologies, Inc. posted the faster year-over-year revenue change (-27.8% vs -38.5%). bioAffinity Technologies, Inc. produced more free cash flow last quarter ($-2.6M vs $-3.6M). Over the past eight quarters, bioAffinity Technologies, Inc.'s revenue compounded faster (-18.6% CAGR vs -25.0%).
bioAffinity Technologies, Inc. is a clinical-stage biotechnology firm focused on developing non-invasive in vitro diagnostic tests for early detection of cancer and respiratory diseases. It serves global healthcare markets, with a core mission to deliver accessible, high-accuracy diagnostic solutions that improve patient outcomes and reduce overall healthcare system costs.
CXApp Inc. is a technology firm specializing in digital workplace experience solutions. It offers cloud-based software tools for employee engagement, office space optimization, visitor management, and hybrid work coordination, serving mid-to-large enterprises across North America, APAC and Europe.
BIAF vs CXAI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.6M | $1.0M |
| Net Profit | $-3.1M | $-5.6M |
| Gross Margin | — | 86.9% |
| Operating Margin | -196.9% | -576.9% |
| Net Margin | -197.0% | -544.1% |
| Revenue YoY | -27.8% | -38.5% |
| Net Profit YoY | -5.7% | -56.7% |
| EPS (diluted) | $-3.59 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $1.6M | $1.0M | ||
| Q3 25 | $1.4M | $1.1M | ||
| Q2 25 | $1.3M | $1.2M | ||
| Q1 25 | $1.9M | $1.2M | ||
| Q4 24 | $2.2M | $1.7M | ||
| Q3 24 | $2.4M | $1.9M | ||
| Q2 24 | $2.4M | $1.8M | ||
| Q1 24 | $2.4M | $1.8M |
| Q4 25 | $-3.1M | $-5.6M | ||
| Q3 25 | $-5.1M | $-3.2M | ||
| Q2 25 | $-4.1M | $-3.1M | ||
| Q1 25 | $-2.7M | $-1.6M | ||
| Q4 24 | $-3.0M | $-3.5M | ||
| Q3 24 | $-2.0M | $-5.4M | ||
| Q2 24 | $-2.1M | $-5.3M | ||
| Q1 24 | $-2.0M | $-5.2M |
| Q4 25 | — | 86.9% | ||
| Q3 25 | — | 89.0% | ||
| Q2 25 | — | 86.0% | ||
| Q1 25 | — | 87.7% | ||
| Q4 24 | — | 86.0% | ||
| Q3 24 | — | 80.4% | ||
| Q2 24 | — | 80.0% | ||
| Q1 24 | — | 82.0% |
| Q4 25 | -196.9% | -576.9% | ||
| Q3 25 | -158.6% | -343.4% | ||
| Q2 25 | -198.2% | -336.1% | ||
| Q1 25 | -141.7% | -306.0% | ||
| Q4 24 | -133.5% | -169.7% | ||
| Q3 24 | -84.0% | -194.3% | ||
| Q2 24 | -87.1% | -206.7% | ||
| Q1 24 | -80.8% | -197.3% |
| Q4 25 | -197.0% | -544.1% | ||
| Q3 25 | -349.3% | -283.4% | ||
| Q2 25 | -319.9% | -256.7% | ||
| Q1 25 | -143.5% | -132.0% | ||
| Q4 24 | -134.4% | -213.6% | ||
| Q3 24 | -85.1% | -286.5% | ||
| Q2 24 | -88.0% | -297.6% | ||
| Q1 24 | -81.5% | -284.4% |
| Q4 25 | $-3.59 | — | ||
| Q3 25 | $-4.74 | — | ||
| Q2 25 | $-0.17 | — | ||
| Q1 25 | $-0.16 | — | ||
| Q4 24 | $-17.27 | — | ||
| Q3 24 | $-4.84 | — | ||
| Q2 24 | $-0.19 | — | ||
| Q1 24 | $-0.20 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $6.4M | $11.1M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $7.3M | $14.0M |
| Total Assets | $11.0M | $32.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $6.4M | $11.1M | ||
| Q3 25 | $7.7M | $5.1M | ||
| Q2 25 | $802.8K | $4.9M | ||
| Q1 25 | $444.7K | $3.9M | ||
| Q4 24 | $1.1M | $4.9M | ||
| Q3 24 | $756.6K | — | ||
| Q2 24 | $801.3K | — | ||
| Q1 24 | $2.5M | — |
| Q4 25 | $7.3M | $14.0M | ||
| Q3 25 | $8.9M | $15.2M | ||
| Q2 25 | $-2.1M | $14.3M | ||
| Q1 25 | $1.4M | $15.6M | ||
| Q4 24 | $2.6M | $15.6M | ||
| Q3 24 | $3.1M | $13.6M | ||
| Q2 24 | $3.4M | $16.3M | ||
| Q1 24 | $5.3M | $20.9M |
| Q4 25 | $11.0M | $32.4M | ||
| Q3 25 | $11.5M | $28.5M | ||
| Q2 25 | $4.8M | $29.6M | ||
| Q1 25 | $5.5M | $29.3M | ||
| Q4 24 | $6.5M | $31.8M | ||
| Q3 24 | $6.6M | — | ||
| Q2 24 | $6.7M | — | ||
| Q1 24 | $8.0M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-2.6M | $-3.6M |
| Free Cash FlowOCF − Capex | $-2.6M | $-3.6M |
| FCF MarginFCF / Revenue | -160.7% | -355.5% |
| Capex IntensityCapex / Revenue | 0.0% | 0.2% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-9.4M | $-10.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-2.6M | $-3.6M | ||
| Q3 25 | $-2.5M | $-2.8M | ||
| Q2 25 | $-2.6M | $-3.0M | ||
| Q1 25 | $-1.6M | $-979.0K | ||
| Q4 24 | $-1.7M | $-2.7M | ||
| Q3 24 | $-1.7M | $-2.1M | ||
| Q2 24 | $-1.5M | $-1.9M | ||
| Q1 24 | $-2.3M | $-650.0K |
| Q4 25 | $-2.6M | $-3.6M | ||
| Q3 25 | $-2.5M | $-2.8M | ||
| Q2 25 | $-2.7M | $-3.0M | ||
| Q1 25 | $-1.7M | $-984.0K | ||
| Q4 24 | $-1.7M | — | ||
| Q3 24 | $-1.7M | $-2.1M | ||
| Q2 24 | $-1.6M | $-1.9M | ||
| Q1 24 | $-2.4M | $-668.0K |
| Q4 25 | -160.7% | -355.5% | ||
| Q3 25 | -171.8% | -248.1% | ||
| Q2 25 | -209.6% | -247.2% | ||
| Q1 25 | -91.3% | -80.4% | ||
| Q4 24 | -76.0% | — | ||
| Q3 24 | -73.1% | -109.3% | ||
| Q2 24 | -65.1% | -108.6% | ||
| Q1 24 | -99.2% | -36.7% |
| Q4 25 | 0.0% | 0.2% | ||
| Q3 25 | 0.3% | 0.4% | ||
| Q2 25 | 1.1% | 0.9% | ||
| Q1 25 | 2.7% | 0.4% | ||
| Q4 24 | 0.0% | 0.0% | ||
| Q3 24 | 0.4% | 0.2% | ||
| Q2 24 | 1.2% | 0.5% | ||
| Q1 24 | 1.7% | 1.0% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
